Release Date: July 20, 2022
Expiration Date: July 20, 2023

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

This activity was previously presented as a live webinar. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Program Overview

In this activity, two leading experts in multiple myeloma provide the latest updates in novel treatment regimens used in practice today and review emerging regimens currently in clinical trials for potential use in the future. They discuss how to currently approach treatment decisions for your patients with newly diagnosed multiple myeloma (NDMM) and strategies that may be incorporated into treatment to impact patient quality of life.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Personalize initial therapy and maintenance approaches for NDMM based on patient and disease characteristics, and the latest evidence from clinical trials and real-world experience
• Identify the most appropriate therapies for patients with NDMM who have underlying comorbidities and who have treatment-related adverse events that necessitate changing therapeutic strategies
• Utilize patient education and shared decision-making approaches to improve patient satisfaction and outcomes

Agenda

• Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes – Sagar Lonial, MD, FACP
• Questions and Answers on Developments in Newly Diagnosed Multiple Myeloma – Saad Z. Usmani, MD, FACP

Instructions for Participation and Credit

This activity is eligible for credit through July 20, 2023. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Sagar Lonial, MD, FACP
Department Chair
Professor of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, Georgia

Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair and Professor of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Lonial’s previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post-transplant immune recovery. More recently, he has focused on combinations of novel agents as therapy for myeloma

Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Myeloma editor for Clinical Lymphoma, Myeloma and Leukemia. He has received the Celgene Young Investigator Award, Indo American Cancer Association (IACA) Lifetime Achievement Award, the COMY Multiple Myeloma Excellence Award for Clinical Science, and the Giants of Cancer Care inductee, and currently holds the Anne and Bernard Gray Family Chair in Cancer.

Saad Z. Usmani, MD, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Saad Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He now serves as the Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center and is Professor of Medicine at Weill Cornell Medical College, New York City.

Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a fellow of the American College of Physicians. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the SWOG Myeloma Committee, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the vice chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Plasma Cell Disorders He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research and the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research. Dr. Usmani has authored/co-authored more than 190 peer-reviewed research manuscripts and 230 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani has research interests focused on plasma cell disorders—in particular, high-risk multiple myeloma.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-22-006-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
	NURSING CREDIT MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-006-155

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Sagar Lonial has relevant financial relationships related to advisory activities from AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation ‒ A Bristol-Myers Squibb Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Novartis AG, and Takeda Oncology. He has received research grant(s) from Bristol-Myers Squibb, Celgene, Janssen, and Takeda. He is on the board of TG Therapeutics, Inc.

Dr. Saad Usmani has relevant financial relationships related to advisory activities and consulting from Endo Pharmaceuticals Inc., Genentech, Inc., Gilead, Oncopeptides, AB, Sanofi, Seattle Genetics, Inc., SecuraBio, and TeneoBio. He has received research grant(s) from Amgen Inc., Array BioPharma, Bristol-Myers Squibb Company, Celgene Corporation - A Bristol-Myers Squibb Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Pharmacyclics, Inc., Sanofi, Seattle Genetics, Skyline Diagnostics B.V, and Takeda Oncology.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.